ID   ARH-77
AC   CVCL_1072
SY   ARH 77; ARH77
DR   BTO; BTO:0002992
DR   CLO; CLO_0001744
DR   CLO; CLO_0001745
DR   EFO; EFO_0002111
DR   CLDB; cl285
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1621
DR   BCRC; 60385
DR   BioSample; SAMN03471407
DR   CCRID; 4201HUM-CCTCC00218
DR   Cell_Model_Passport; SIDM00900
DR   ChEMBL-Cells; CHEMBL3308536
DR   ChEMBL-Targets; CHEMBL2366241
DR   CLS; 300306
DR   Cosmic; 759914
DR   Cosmic; 886086
DR   Cosmic; 888020
DR   Cosmic; 906765
DR   Cosmic; 919148
DR   Cosmic; 999792
DR   Cosmic-CLP; 906765
DR   DepMap; ACH-002210
DR   DSMZ; ACC-512
DR   DSMZCellDive; ACC-512
DR   ECACC; 88121201
DR   EGA; EGAS00001000978
DR   GDSC; 906765
DR   GEO; GSM1374393
DR   GEO; GSM1669601
DR   IARC_TP53; 21176
DR   IGRhCellID; ARH77
DR   Lonza; 593
DR   PharmacoDB; ARH77_64_2019
DR   PubChem_Cell_line; CVCL_1072
DR   Wikidata; Q54750440
RX   DOI=10.1007/0-306-46877-8_4;
RX   Patent=US4730036;
RX   PubMed=566614;
RX   PubMed=2140233;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=4042077;
RX   PubMed=6605913;
RX   PubMed=7140810;
RX   PubMed=7579375;
RX   PubMed=8051085;
RX   PubMed=9510473;
RX   PubMed=10516762;
RX   PubMed=10936422;
RX   PubMed=14555701;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
CC   Problematic cell line: Misclassified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=4042077; PubMed=7579375; PubMed=10516762).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 110.4 hours (PubMed=566614); ~30 hours (DSMZ=ACC-512).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (Cosmic-CLP).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.24%; Native American=0.38%; East Asian, North=0%; East Asian, South=2.18%; South Asian=8.63%; European, North=25.32%; European, South=61.25% (PubMed=30894373).
CC   Misspelling: AHR 77; Note=Occasionally.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC
ST   Amelogenin: X
ST   CSF1PO: 6,10
ST   D12S391: 19,20
ST   D13S317: 11,13
ST   D16S539: 9,13
ST   D18S51: 14,16
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 17
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D6S1043: 11,19
ST   D7S820: 7,12
ST   D8S1179: 14,15
ST   FGA: 20,21
ST   Penta D: 10
ST   Penta E: 12
ST   TH01: 8,9.3
ST   TPOX: 8
ST   vWA: 17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   33Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
RX   Patent=US4730036;
RA   Ralph P., Welte K.;
RT   "Purifications of B-cell inducing factor (BIF) and B-cell growth
RT   factor (BGF).";
RL   Patent number US4730036, 08-Mar-1988.
RX   PubMed=566614;
RA   Burk K.H., Drewinko B., Trujillo J.M., Ahearn M.J.;
RT   "Establishment of a human plasma cell line in vitro.";
RL   Cancer Res. 38:2508-2513(1978).
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C.";
RL   Leuk. Res. 9:549-559(1985).
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
RX   PubMed=4042077; DOI=10.1002/1097-0142(19851115)56:10<2544::AID-CNCR2820561039>3.0.CO;2-g;
RA   Ralph P.;
RT   "The human B-cell lineage cell line ARH-77.";
RL   Cancer 56:2544-2545(1985).
RX   PubMed=6605913; DOI=10.1016/0165-2478(83)90049-4;
RA   Ralph P., Saiki O., Maurer D.H., Welte K.;
RT   "IgM and IgG secretion in human B-cell lines regulated by
RT   B-cell-inducing factors (BIF) and phorbol ester.";
RL   Immunol. Lett. 7:17-23(1983).
RX   PubMed=7140810; DOI=10.1002/eji.1830120804;
RA   Edwards P.A.W., Smith C.M., Neville A.M., O'Hare M.J.;
RT   "A human-hybridoma system based on a fast-growing mutant of the ARH-77
RT   plasma cell leukemia-derived line.";
RL   Eur. J. Immunol. 12:641-648(1982).
RX   PubMed=7579375; DOI=10.1182/blood.V86.10.4001.bloodjournal86104001;
RA   Pellat-Deceunynck C., Amiot M., Bataille R., Van Riet I., Van Camp B.,
RA   Omede P., Boccadoro M.;
RT   "Human myeloma cell lines as a tool for studying the biology of
RT   multiple myeloma: a reappraisal 18 years after.";
RL   Blood 86:4001-4002(1995).
RX   PubMed=8051085; DOI=10.1016/S0021-9258(17)32120-8;
RA   Liebersbach B.F., Sanderson R.D.;
RT   "Expression of syndecan-1 inhibits cell invasion into type I
RT   collagen.";
RL   J. Biol. Chem. 269:20013-20019(1994).
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
RX   PubMed=10516762; DOI=10.1038/sj.leu.2401510;
RA   Drexler H.G., Dirks W.G., MacLeod R.A.F.;
RT   "False human hematopoietic cell lines: cross-contaminations and
RT   misinterpretations.";
RL   Leukemia 13:1601-1607(1999).
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
RX   PubMed=14555701;
RA   Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D.,
RA   Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest by G-quadruplex
RT   interactive agent in multiple myeloma.";
RL   Mol. Cancer Ther. 2:825-833(2003).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).